Loading…
GMAB
Genmab A/s
NASDAQ· Healthcare· Biotechnology· CUSIP 372303206
$40.00+1.09%Price as of Oct 23, 00:47 UTC · updated once a day, after the close
At a glance
Genmab A/s (GMAB) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Copenhagen, Denmark and has 3,119 employees. The company is worth $24.6B and trades at 31.5x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $3.72B in fiscal 2025, up 19.2% from the year before. Net income was $963M. The share price is within 3% of its 52-week high. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $96.64M. In that quarter, 4 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $24.6B
- P/E
- 31.5x
- Forward P/E
- 26.4x
- P/B
- 4.0x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $1.27
- ROE
- 14.00%
- Profit margin
- 19.07%
- Revenue growth
- +24.90%
- Beta
- 0.65
- 52-week high
- $40.17
- 52-week low
- $23.62
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Renaissance TechnologiesReducedRenaissance Technologies · Q2 2026$96.64M3.52M shares · 0.1% of portfolio
- Two SigmaAddedTwo Sigma Investments · Q2 2026$96.33M3.51M shares · 0.1% of portfolio
Ken GriffinNew positionCitadel Advisors · Q2 2026$68.02M2.48M shares · 0.0% of portfolio- Israel EnglanderAddedMillennium Management · Q2 2026$25.01M910.6K shares · 0.0% of portfolio
- Steve CohenNew positionPoint72 Asset Management · Q2 2026$3.73M135.65K shares · 0.0% of portfolio
- Cliff AsnessHeldAQR Capital Management · Q2 2026$2.91M106.1K shares · 0.0% of portfolio
Price over time
▼ -3.9% over 5Y.
today you would have $828.85▼ -17.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $30.80 | $20.87 | $31.84 | $42.38 | $39.56 | |
| P/E | 26.6x | 20.0x | 12.3x | 33.2x | 35.2x | — |
| P/S | 0.7x | 0.5x | 0.4x | 0.9x | 1.3x | — |
| P/B | 0.4x | 0.3x | 0.3x | 0.4x | 0.7x | — |
| EPS | $1.54 | $1.69 | $0.96 | $1.20 | — | |
| Profit margin | 31.35% | 25.89% | 36.30% | 26.40% | 37.59% | — |
| ROE | 18.23% | 16.47% | 22.06% | 13.46% | 19.98% | — |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$16.89
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
$10.77
Earnings growing 8.5% a year plus a 0.0% dividend yield. Growth capped at 25%.
Earnings
$30.84
Median P/E of 24.3 among peers in the sector.
Earnings
$33.83
Median P/E of 26.6 across this company’s own years on record.
Cash flow
$328.33
Cash flow growing 8.5% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$244.79
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Earnings $23.08 (avg. of 4)+Cash flow $328.33+Operating $244.79÷ 3 =$198.74
$198.74
6 methods answered, across 3 families.
$149.05
Room for errors in the reported numbers.
$40.00
+396.8% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| UTHRUNITED THERAPEUTICS Corp | $584.79 | 20.9x | 3.9x | 0.00% | 19.32% | $25.08B |
| INCYIncyte Corp | $116.93 | 14.5x | 3.7x | 0.00% | 30.67% | $23.7B |
| PHGKoninklijke Philips NV | $26.92 | 20.1x | 2.0x | 3.75% | 10.15% | $26.31B |
| STESTERIS plc | $232.22 | 27.1x | 3.1x | 1.11% | 11.39% | $22.64B |
| LHLabcorp Holdings Inc | $329.93 | 27.3x | 3.1x | 0.87% | 11.73% | $26.76B |
| DGXQuest Diagnostics Inc | $243.28 | 25.8x | 3.6x | 1.41% | 14.60% | $26.85B |
About the company
- 3,119
- Copenhagen, Denmark